<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NESINA- alogliptin benzoate tablet, film coated </strong><br>Takeda Pharmaceuticals America, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use NESINA safely and effectively. See full prescribing information for NESINA.<br><br>NESINA (alogliptin) tablets<br>Initial U.S. Approval: 2013</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Warnings and Precautions (<a href="#ID_803ec09c-d703-43c2-8e31-dbfeac2aed31">5.5</a>)                         8/2015 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">NESINA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. (<a href="#i4i_section_id_d0f51e0f-a78f-431b-9495-5f5d5f508e1b">1.1</a>,<a href="#i4i_clinical_studies_id_01eab70c-9c39-45fd-a847-3c119cde8163"> 14</a>) </p>
<p class="Highlighta">Limitation of Use: Not for treatment of type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#i4i_section_id_5a06b0d8-d37d-4a29-ad5e-9417f0d38149">1.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>The recommended dose in patients with normal renal function or mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is 25 mg once daily. (<a href="#i4i_section_id_8f81ae48-c4e2-43c4-a99c-edf8cc4606d2">2.1</a>)</dd>
<dt>•</dt>
<dd>Can be taken with or without food. (<a href="#i4i_section_id_8f81ae48-c4e2-43c4-a99c-edf8cc4606d2">2.1</a>)</dd>
<dt>•</dt>
<dd>Adjust dose if moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD). (<a href="#_Ref">2.2</a>)</dd>
</dl>
<table width="100%">
<col width="23%">
<col width="25%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top"><p class="Highlighta"><span class="Bold">Degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span> </p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="Highlighta"><span class="Bold">Creatinine Clearance (mL/min)</span> </p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="Highlighta"><span class="Bold">Recommended Dosing</span> </p></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">Moderate </p></td>
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">≥30 to &lt;60 </p></td>
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">12.5 mg once daily </p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">Severe/ESRD </p></td>
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">&lt;30 </p></td>
<td class="Botrule" align="center" valign="middle"><p class="Highlighta">6.25 mg once daily </p></td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 25 mg, 12.5 mg and 6.25 mg (<a href="#i4i_dosage_form_strength_id_1bade720-fcb3-4b27-90e3-050a2ea4c1b7">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to alogliptin-containing products, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or severe cutaneous adverse reactions. (<a href="#i4i_contraindications_id_8a3fc10d-d149-4f47-a760-9e353f110320">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span>: There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, promptly discontinue NESINA. (<a href="#i4i_section_id_3a7947a6-f05e-4a5f-953b-d593c1f70b44">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with NESINA such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe cutaneous adverse reactions. In such cases, promptly discontinue NESINA, assess for other potential causes, institute appropriate monitoring and treatment and initiate alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#i4i_section_id_6721bff3-09c9-437b-a6a0-4111c2dfb662">5.2</a>)</dd>
<dt>•</dt>
<dd>Hepatic effects: Postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, sometimes fatal. Causality cannot be excluded. If <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is detected, promptly interrupt NESINA and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart NESINA if <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is confirmed and no alternative etiology can be found. (<a href="#ID_ef10a37a-cc2f-4d28-9f21-4e5a445c3de4">5.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: When an insulin secretagogue (e.g., sulfonylurea) or insulin is used in combination with NESINA, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. (<a href="#ID_8896141c-8d34-473a-b6e8-0be6bf945cec">5.4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>: Severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> and discontinue drug if appropriate. (<a href="#ID_803ec09c-d703-43c2-8e31-dbfeac2aed31">5.5</a>)</dd>
<dt>•</dt>
<dd>Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with NESINA or any other antidiabetic drug. (<a href="#ID_5a1e226c-1169-4cc0-b3b4-b233145c3a28">5.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse reactions (reported in ≥4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) are: <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>. (<a href="#i4i_section_id_d24c435d-44b9-416b-8423-2b5c513c2dc9">6.1</a>) </p>
<p class="Highlighta">  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
<p class="Highlighta"><span class="Bold"> </span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div><div><div></div></div></div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Monotherapy and Combination Therapy</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange">5.5 Severe and Disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">	7 DRUG INTERACTIONS	</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Patients with Inadequate Glycemic Control on Diet and Exercise</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Combination Therapy</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Instructions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_d5f0d268-3320-4b04-b796-18a355221c74"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0f51e0f-a78f-431b-9495-5f5d5f508e1b"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Monotherapy and Combination Therapy</h2>
<p class="First">NESINA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in multiple clinical settings <span class="Italics">[see<a href="#i4i_clinical_studies_id_01eab70c-9c39-45fd-a847-3c119cde8163"> Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a06b0d8-d37d-4a29-ad5e-9417f0d38149"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Limitation of Use</h2>
<p class="First">NESINA should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, as it would not be effective in these settings.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a0ddabee-c298-413c-a139-e79adbd1428a"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f81ae48-c4e2-43c4-a99c-edf8cc4606d2"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">The recommended dose of NESINA is 25 mg once daily.</p>
<p>NESINA may be taken with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7dd1a407-4920-43f4-9f6a-c61e2198c5c5"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment of NESINA is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CrCl] ≥60 mL/min).</p>
<p>The dose of NESINA is 12.5 mg once daily for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≥30 to &lt;60 mL/min).</p>
<p>The dose of NESINA is 6.25 mg once daily for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≥15 to &lt;30 mL/min) or with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) (CrCl &lt;15 mL/min or requiring hemodialysis). NESINA may be administered without regard to the timing of dialysis. NESINA has not been studied in patients undergoing peritoneal dialysis <span class="Italics">[see<a href="#i4i_pharmacokinetics_id_d0fc4860-2dc6-4c89-bd0d-9d740ab7ff3f"> Clinical Pharmacology (12.3)</a>].</span></p>
<p>Because there is a need for dose adjustment based upon renal function, assessment of renal function is recommended prior to initiation of NESINA therapy and periodically thereafter.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_1bade720-fcb3-4b27-90e3-050a2ea4c1b7"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>•</dt>
<dd> 25 mg tablets are light red, oval, biconvex, film-coated, with "TAK ALG-25" printed on one side.</dd>
<dt>•</dt>
<dd> 12.5 mg tablets are yellow, oval, biconvex, film-coated, with "TAK ALG-12.5" printed on one side.</dd>
<dt>•</dt>
<dd> 6.25 mg tablets are light pink, oval, biconvex, film-coated, with "TAK ALG-6.25" printed on one side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_8a3fc10d-d149-4f47-a760-9e353f110320"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">History of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to alogliptin-containing products, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or severe cutaneous adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_c1a3543b-31a5-442d-83cc-91aaa27b45ac"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a7947a6-f05e-4a5f-953b-d593c1f70b44"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> in patients taking NESINA. After initiation of NESINA, patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is suspected, NESINA should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a history of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> are at increased risk for the development of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> while using NESINA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6721bff3-09c9-437b-a6a0-4111c2dfb662"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">There have been postmarketing reports of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in patients treated with NESINA. These reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe cutaneous adverse reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. If a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected, discontinue NESINA, assess for other potential causes for the event and institute alternative treatment for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see <a href="#i4i_section_id_d3e305a0-48d5-40f6-854a-f05872f20b75">Adverse Reactions (6.2)</a>]</span>. Use caution in a patient with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with NESINA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ef10a37a-cc2f-4d28-9f21-4e5a445c3de4"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatic Effects</h2>
<p class="First">There have been postmarketing reports of fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking NESINA, although some of the reports contain insufficient information necessary to establish the probable cause <span class="Italics">[see <a href="#i4i_section_id_d3e305a0-48d5-40f6-854a-f05872f20b75">Adverse Reactions (6.2)</a>]</span>. In randomized controlled studies, serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) elevations greater than three times the upper limit of normal (ULN) were observed: 1.3% in alogliptin-treated patients and 1.5% in all comparator-treated patients.</p>
<p>Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> may have <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">fatty liver</span> disease, which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel and assessing the patient before initiating NESINA therapy is recommended. In patients with abnormal liver tests, NESINA should be initiated with caution.</p>
<p>Measure liver tests promptly in patients who report symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In this clinical context, if the patient is found to have clinically significant liver enzyme elevations and if abnormal liver tests persist or worsen, NESINA should be interrupted and investigation done to establish the probable cause. NESINA should not be restarted in these patients without another explanation for the liver test abnormalities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8896141c-8d34-473a-b6e8-0be6bf945cec"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use with Medications Known to Cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Insulin and insulin secretagogues, such as sulfonylureas, are known to cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> when used in combination with NESINA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_803ec09c-d703-43c2-8e31-dbfeac2aed31"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.5 Severe and Disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">There have been postmarketing reports of severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> and discontinue drug if appropriate.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5a1e226c-1169-4cc0-b3b4-b233145c3a28"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with NESINA or any other antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f9d79927-8169-4021-b9eb-d78a57f93713"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d24c435d-44b9-416b-8423-2b5c513c2dc9"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Approximately 8500 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated with NESINA in 14 randomized, double-blind, controlled clinical trials with approximately 2900 subjects randomized to placebo and approximately 2200 to an active comparator. The mean exposure to NESINA was 40 weeks with more than 2400 subjects treated for more than one year. Among these patients, 63% had a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 51% had a history of <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, 25% had a history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, 8% had a history of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and 7% had a history of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. The mean duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> was seven years, the mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) was 31 kg/m<span class="Sup">2</span> (51% of patients had a BMI ≥30 kg/m<span class="Sup">2</span>), and the mean age was 57 years (24% of patients ≥65 years of age).</p>
<p>Two placebo-controlled monotherapy trials of 12 and 26 weeks of duration were conducted in patients treated with NESINA 12.5 mg daily, NESINA 25 mg daily and placebo. Four placebo-controlled add-on combination therapy trials of 26 weeks duration were also conducted: with metformin, with a sulfonylurea, with a thiazolidinedione and with insulin.</p>
<p>Four placebo-controlled and one active-controlled trials of 16 weeks up through two years in duration were conducted in combination with metformin, in combination with pioglitazone and with pioglitazone added to a background of metformin therapy.</p>
<p>Three active-controlled trials of 52 weeks in duration were conducted in patients treated with pioglitazone and metformin, in combination with metformin and as monotherapy compared to glipizide.</p>
<p>In a pooled analysis of these 14 controlled clinical trials, the overall incidence of adverse events was 66% in patients treated with NESINA 25 mg compared to 62% with placebo and 70% with active comparator. Overall discontinuation of therapy due to adverse events was 4.7% with NESINA 25 mg compared to 4.5% with placebo or 6.2% with active comparator.</p>
<p>Adverse reactions reported in ≥4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo are summarized in Table 1.</p>
<table width="100%">
<col width="42%">
<col width="19%">
<col width="19%">
<col width="19%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4" valign="top"><p class="First"><span class="Bold">Table 1. Adverse Reactions Reported in ≥4% Patients Treated with NESINA 25 mg and More Frequently Than in Patients Given Placebo in Pooled Studies</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Number of Patients (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA</span><br><span class="Bold">25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Active </span></p>
<p><span class="Bold">Comparator</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=5902</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=2926</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=2257</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">257 (4.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">89 (3.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">113 (5.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">247 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">72 (2.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">121 (5.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">247 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">61 (2.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">113 (5.0)</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_21719608-b4fb-4528-b1e2-c44261b54e67"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span></p>
<p>In the clinical trial program, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> was reported in 11 of 5902 (0.2%) patients receiving NESINA 25 mg daily compared to five of 5183 (&lt;0.1%) patients receiving all comparators.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_112bcb9f-e5ba-4553-9ed6-50191b1d745f"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>In a pooled analysis, the overall incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> was 0.6% with NESINA 25 mg compared to 0.8% with all comparators. A single event of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> was reported in a patient treated with NESINA 25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f810512-8fae-4d57-87f5-f000bad20587"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p>Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>In the monotherapy study, the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 1.5% in patients treated with NESINA compared to 1.6% with placebo. The use of NESINA as add-on therapy to glyburide or insulin did not increase the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> compared to placebo. In a monotherapy study comparing NESINA to a sulfonylurea in elderly patients, the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 5.4% with NESINA compared to 26% with glipizide <span class="Italics">(Table 2)</span>.</p>
<table width="100%">
<col width="43%">
<col width="25%">
<col width="31%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Adverse reactions of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were based on all reports of symptomatic and asymptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; a concurrent glucose measurement was not required; intent-to-treat population.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Severe events of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were defined as those events requiring medical assistance or exhibiting depressed level or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 2. Incidence and Rate of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><span class="Bold"> in Placebo and Active-Controlled Studies when NESINA Was Used as Add-On Therapy to Glyburide, Insulin, Metformin, Pioglitazone or Compared to Glipizide</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Add-On to Glyburide</span><br><span class="Bold">(26 Weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+ Glyburide</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Glyburide</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=198</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=99</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Overall (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">19 (9.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">11 (11.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Severe (%)<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Add-On to Insulin (± Metformin)</span><br><span class="Bold">(26 Weeks) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+ Insulin </span></p>
<p><span class="Bold">(± Metformin)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Insulin </span></p>
<p><span class="Bold">(± Metformin)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=129</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=129</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Overall (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">35 (27)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">31 (24)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Severe (%)<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1 (0.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2 (1.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Add-On to Metformin</span><br><span class="Bold">(26 Weeks) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+ Metformin</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=207</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=104</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Overall (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3 (2.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Severe (%)<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Add-On to Pioglitazone</span><br><span class="Bold">(± Metformin or Sulfonylurea)</span><br><span class="Bold">(26 Weeks) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+ Pioglitazone</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Pioglitazone</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=199</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=97</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Overall (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14 (7.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5 (5.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Severe (%)<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Compared to Glipizide</span><br><span class="Bold">(52 Weeks) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Glipizide</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=222</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=219</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Overall (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12 (5.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">57 (26)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Severe (%)<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3 (1.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Add-On to Metformin</span><br><span class="Bold">(26 Weeks) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">NESINA 25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Metformin 500 mg </span></p>
<p><span class="Bold">twice daily</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=112</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=109</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Overall (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2 (1.8)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2 (1.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Severe (%)<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Add-On to Metformin Compared to Glipizide</span><br><span class="Bold">(52 Weeks) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+ Metformin</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Glipizide</span></p>
<p><span class="Bold">+ Metformin</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=877</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=869</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Overall (%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">12 (1.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">207 (23.8)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Severe (%)<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">4 (0.5)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2dece96a-d052-495a-9425-ebd12c08e5a3"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold">Vital Signs</span></p>
<p>No clinically meaningful changes in vital signs or in electrocardiograms were observed in patients treated with NESINA.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_028104ed-1372-42ec-9065-5c4789c944fe"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests</span></p>
<p>No clinically meaningful changes in hematology, serum chemistry or urinalysis were observed in patients treated with NESINA.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3e305a0-48d5-40f6-854a-f05872f20b75"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during the postmarketing use of NESINA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and severe cutaneous adverse reactions, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, hepatic enzyme elevations, <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">fulminant hepatic failure</span>, severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> and <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_3a7947a6-f05e-4a5f-953b-d593c1f70b44">5.1</a>, <a href="#ID_8896141c-8d34-473a-b6e8-0be6bf945cec">5.2</a>, <a href="#ID_ef10a37a-cc2f-4d28-9f21-4e5a445c3de4">5.3</a>, <a href="#ID_803ec09c-d703-43c2-8e31-dbfeac2aed31">5.5</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_725c9b07-5304-474a-979e-ffa84015e30b"></a><a name="section-7"></a><p></p>
<h1>	7 DRUG INTERACTIONS	</h1>
<p class="First">NESINA is primarily renally excreted. Cytochrome (CYP) P450-related metabolism is negligible. No significant drug-drug interactions were observed with the CYP-substrates or inhibitors tested or with renally excreted drugs <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_d0fc4860-2dc6-4c89-bd0d-9d740ab7ff3f">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_919951f1-a9e3-4a5f-8773-bb026c5be1b5"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_963528d2-e468-45ce-8e07-a7f82e32ecac"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_87230ef6-b019-4d5d-b589-732700eda267"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p>No adequate or well-controlled studies in pregnant women have been conducted with NESINA. Based on animal data, NESINA is not predicted to increase the risk of developmental abnormalities. Because animal reproduction studies are not always predictive of human risk and exposure, NESINA, like other antidiabetic medications, should be used during pregnancy only if clearly needed.</p>
<p>Alogliptin administered to pregnant rabbits and rats during the period of organogenesis was not teratogenic at doses of up to 200 mg/kg and 500 mg/kg, or 149 times and 180 times, respectively, the clinical dose based on plasma drug exposure (AUC). </p>
<p>Doses of alogliptin up to 250 mg/kg (approximately 95 times clinical exposure based on AUC) given to pregnant rats from gestation Day 6 to lactation Day 20 did not harm the developing embryo or adversely affect growth and development of offspring.</p>
<p>Placental transfer of alogliptin into the fetus was observed following oral dosing to pregnant rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_7721a4a2-ecab-46d6-b5d1-7de27d44e618"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Alogliptin is secreted in the milk of lactating rats in a 2:1 ratio to plasma. It is not known whether alogliptin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NESINA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_471e9fbc-3349-4120-afb0-4250a2566227"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of NESINA in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_3276b871-fe2a-4420-925c-38a55135ca4c"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of patients (N=8507) in clinical safety and efficacy studies treated with NESINA, 2064 (24.3%) patients were 65 years and older and 341 (4%) patients were 75 years and older. No overall differences in safety or effectiveness were observed between patients 65 years and over and younger patients. While this clinical experience has not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5e78b66c-a1cc-4608-a2d6-19234f6a1c6f"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustments are required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade A and B) based on insignificant change in systemic exposures (e.g., AUC) compared to subjects with normal hepatic function in a pharmacokinetic study. NESINA has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade C). Use caution when administering NESINA to patients with liver disease <span class="Italics">[see <a href="#ID_ef10a37a-cc2f-4d28-9f21-4e5a445c3de4">Warnings and Precautions (5.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_c1f22039-e5b9-4384-9a76-72c3edf0aaaa"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The highest doses of NESINA administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (equivalent to 32 times and 16 times the maximum recommended clinical dose of 25 mg, respectively). No serious adverse events were observed at these doses.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it is reasonable to institute the necessary clinical monitoring and supportive therapy as dictated by the patient's clinical status. Per clinical judgment, it may be reasonable to initiate removal of unabsorbed material from the gastrointestinal tract.</p>
<p>Alogliptin is minimally dialyzable; over a three-hour hemodialysis session, approximately 7% of the drug was removed. Therefore, hemodialysis is unlikely to be beneficial in an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situation. It is not known if NESINA is dialyzable by peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_1d9e849e-583d-486c-bdc5-aee7e34ced2a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">NESINA tablets contain the active ingredient alogliptin, which is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4).</p>
<p>Chemically, alogliptin is prepared as a benzoate salt, which is identified as 2-({6-[(3<span class="Italics">R</span>)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2<span class="Italics">H</span>)-yl}methyl)benzonitrile monobenzoate. It has a molecular formula of C<span class="Sub">18</span>H<span class="Sub">21</span>N<span class="Sub">5</span>O<span class="Sub">2</span>•C<span class="Sub">7</span>H<span class="Sub">6</span>O<span class="Sub">2 </span>and a molecular weight of 461.51 daltons. The structural formula is:</p>
<div class="Figure">
<a name="id1218"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0&amp;name=d74fabc5-733f-4fbf-ad1c-d23fae6802fd-01.jpg">
</div>
<p>Alogliptin benzoate is a white to off-white crystalline powder containing one asymmetric carbon in the aminopiperidine moiety. It is soluble in dimethylsulfoxide, sparingly soluble in water and methanol, slightly soluble in ethanol and very slightly soluble in octanol and isopropyl acetate.</p>
<p>Each NESINA tablet contains 34 mg, 17 mg or 8.5 mg alogliptin benzoate, which is equivalent to 25 mg, 12.5 mg or 6.25 mg, respectively, of alogliptin and the following inactive ingredients: mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium and magnesium stearate. In addition, the film coating contains the following inactive ingredients: hypromellose, titanium dioxide, ferric oxide (red or yellow) and polyethylene glycol, and is marked with printing ink (Gray F1).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_53d697cf-5403-4913-8a5c-6dcdc9982330"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_42c697a3-21a1-44e0-9d9f-fc22102a6d32"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved. Alogliptin is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Alogliptin selectively binds to and inhibits DPP-4 but not DPP-8 or DPP-9 activity <span class="Italics">in vitro </span>at concentrations approximating therapeutic exposures.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_6605f7e2-5a65-41cd-a076-dc4a5d24782e"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Single-dose administration of NESINA to healthy subjects resulted in a peak inhibition of DPP-4 within two to three hours after dosing. The peak inhibition of DPP-4 exceeded 93% across doses of 12.5 mg to 800 mg. Inhibition of DPP-4 remained above 80% at 24 hours for doses greater than or equal to 25 mg. Peak and total exposure over 24 hours to active GLP-1 were three- to four-fold greater with NESINA (at doses of 25 to 200 mg) than placebo. In a 16-week, double-blind, placebo-controlled study, NESINA 25 mg demonstrated decreases in postprandial glucagon while increasing postprandial active GLP-1 levels compared to placebo over an eight-hour period following a standardized meal. It is unclear how these findings relate to changes in overall glycemic control in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. In this study, NESINA 25 mg demonstrated decreases in two-hour postprandial glucose compared to placebo (-30 mg/dL versus 17 mg/dL, respectively).</p>
<p>Multiple-dose administration of alogliptin to patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> also resulted in a peak inhibition of DPP-4 within one to two hours and exceeded 93% across all doses (25 mg, 100 mg and 400 mg) after a single dose and after 14 days of once-daily dosing. At these doses of NESINA, inhibition of DPP-4 remained above 81% at 24 hours after 14 days of dosing.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_70208a81-e4a9-4162-bed8-6a195e6dae5e"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Cardiac Electrophysiology</span></p>
<p>In a randomized, placebo-controlled, four-arm, parallel-group study, 257 subjects were administered either alogliptin 50 mg, alogliptin 400 mg, moxifloxacin 400 mg or placebo once daily for a total of seven days. No increase in QTc was observed with either dose of alogliptin. At the 400 mg dose, peak alogliptin plasma concentrations were 19-fold higher than the peak concentrations following the maximum recommended clinical dose of 25 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d0fc4860-2dc6-4c89-bd0d-9d740ab7ff3f"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of NESINA has been studied in healthy subjects and in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. After administration of single, oral doses up to 800 mg in healthy subjects, the peak plasma alogliptin concentration (median T<span class="Sub">max</span>) occurred one to two hours after dosing. At the maximum recommended clinical dose of 25 mg, NESINA was eliminated with a mean terminal half-life (T<span class="Sub">1/2</span>) of approximately 21 hours.</p>
<p>After multiple-dose administration up to 400 mg for 14 days in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, accumulation of alogliptin was minimal with an increase in total (i.e., AUC) and peak (i.e., C<span class="Sub">max</span>) alogliptin exposures of 34% and 9%, respectively. Total and peak exposure to alogliptin increased proportionally across single doses and multiple doses of alogliptin ranging from 25 mg to 400 mg. The intersubject coefficient of variation for alogliptin AUC was 17%. The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_131ecd90-4b52-48da-ba36-ace15d25050c"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>The absolute bioavailability of NESINA is approximately 100%. Administration of NESINA with a high-fat meal results in no significant change in total and peak exposure to alogliptin. NESINA may therefore be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04492bbd-296a-4f14-a59b-b5263757bad5"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.</p>
<p>Alogliptin is 20% bound to plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_29fe5b01-5810-46ae-b673-a460c112b724"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>Alogliptin does not undergo extensive metabolism and 60% to 71% of the dose is excreted as unchanged drug in the urine.</p>
<p>Two minor metabolites were detected following administration of an oral dose of [<span class="Sup">14</span>C] alogliptin, <span class="Italics">N</span>-demethylated, M-I (&lt;1% of the parent compound), and <span class="Italics">N</span>-acetylated alogliptin, M-II (&lt;6% of the parent compound). M-I is an active metabolite and is an inhibitor of DPP-4 similar to the parent molecule; M-II does not display any inhibitory activity toward DPP-4 or other DPP-related enzymes. <span class="Italics">In vitro </span>data indicate that CYP2D6 and CYP3A4 contribute to the limited metabolism of alogliptin.</p>
<p>Alogliptin exists predominantly as the (<span class="Italics">R</span>)-enantiomer (&gt;99%) and undergoes little or no chiral conversion <span class="Italics">in vivo</span> to the (<span class="Italics">S</span>)-enantiomer. The (<span class="Italics">S</span>)-enantiomer is not detectable at the 25 mg dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ccbfc64-ff1d-406f-a551-987901646e4a"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>The primary route of elimination of [<span class="Sup">14</span>C] alogliptin-derived radioactivity occurs via renal excretion (76%) with 13% recovered in the feces, achieving a total recovery of 89% of the administered radioactive dose. The renal clearance of alogliptin (9.6 L/hr) indicates some active renal tubular secretion and systemic clearance was 14.0 L/hr.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e9d2511-374b-45b1-9bef-4423547c26ee"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_103fcd57-5def-4795-95f5-c551122cc927"></a><a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>A single-dose, open-label study was conducted to evaluate the pharmacokinetics of alogliptin 50 mg in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic renal impairment</span> compared with healthy subjects. </p>
<p>In patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [CrCl] ≥60 to &lt;90 mL/min), an approximate 1.2-fold increase in plasma AUC of alogliptin was observed. Because increases of this magnitude are not considered clinically relevant, dose adjustment for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended.</p>
<p>In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≥30 to &lt;60 mL/min), an approximate two-fold increase in plasma AUC of alogliptin was observed. To maintain similar systemic exposures of NESINA to those with normal renal function, the recommended dose is 12.5 mg once daily in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl ≥15 to &lt;30 mL/min) and ESRD (CrCl &lt;15 mL/min or requiring dialysis), an approximate three- and four-fold increase in plasma AUC of alogliptin were observed, respectively. Dialysis removed approximately 7% of the drug during a three-hour dialysis session. NESINA may be administered without regard to the timing of the dialysis. To maintain similar systemic exposures of NESINA to those with normal renal function, the recommended dose is 6.25 mg once daily in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, as well as in patients with ESRD  requiring dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8a42fa7-f049-4de4-9a72-5cfd903136b6"></a><a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade B) compared to healthy subjects. The magnitude of these reductions is not considered to be clinically meaningful. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Grade C) have not been studied. Use caution when administering NESINA to patients with liver disease <span class="Italics">[see <a href="#ID_5e78b66c-a1cc-4608-a2d6-19234f6a1c6f">Use in Specific Populations (8.6)</a> and <a href="#ID_ef10a37a-cc2f-4d28-9f21-4e5a445c3de4">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1bdb5865-fb8b-4240-bb1b-cc94daa993d5"></a><a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Gender</span></span></p>
<p>No dose adjustment of NESINA is necessary based on gender. Gender did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_526c5cf6-f870-4426-958c-4a025357385a"></a><a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Geriatric</span></span></p>
<p>No dose adjustment of NESINA is necessary based on age. Age did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d59bc55a-c0b1-4716-a2bb-fd9c4a3531f1"></a><a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Pediatric</span></span></p>
<p>Studies characterizing the pharmacokinetics of alogliptin in pediatric patients have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3c98aca-b170-448b-aebd-e64e9987ef70"></a><a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Race</span></span></p>
<p>No dose adjustment of NESINA is necessary based on race. Race (White, Black, and Asian) did not have any clinically meaningful effect on the pharmacokinetics of alogliptin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8852880f-bfca-4a80-9790-45e041977af6"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_837edbe1-2bdf-4815-af46-62108f8971c6"></a><a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">In Vitro Assessment of Drug Interactions</span></span></p>
<p><span class="Italics">In vitro</span> studies indicate that alogliptin is neither an inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4, nor an inhibitor of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP2D6 at clinically relevant concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e7549c08-f588-4cad-ac09-e81136ab335c"></a><a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">In Vivo Assessment of Drug Interactions</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e7ae36c5-43ed-4dcc-b3c8-0f5419849c40"></a><a name="section-11.3.6.2.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Underline">Effects of Alogliptin on the Pharmacokinetics of Other Drugs</span></span></p>
<p>In clinical studies, alogliptin did not meaningfully increase the systemic exposure to the following drugs that are metabolized by CYP isozymes or excreted unchanged in urine <span class="Italics">(Figure 1)</span>. No dose adjustment of NESINA is recommended based on results of the described pharmacokinetic studies.</p>
<p><span class="Bold">Figure 1. Effect of Alogliptin on the Pharmacokinetic Exposure to Other Drugs</span></p>
<div class="Figure">
<a name="id14762760"></a><img alt="Figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0&amp;name=d74fabc5-733f-4fbf-ad1c-d23fae6802fd-03.jpg">
</div>
<p><span class="Sup">*</span>Warfarin was given once daily at a stable dose in the range of 1 mg to 10 mg. Alogliptin had no significant effect on the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) or International Normalized Ratio (INR).</p>
<p><span class="Sup">**</span>Caffeine (1A2 substrate), tolbutamide (2C9 substrate), dextromethorphan (2D6 substrate), midazolam (3A4 substrate)  and fexofenadine (P-gp substrate) were administered as a cocktail.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b39a505-bad6-43a1-978e-c6d04b3d7d9a"></a><a name="section-11.3.6.2.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Underline">Effects of Other Drugs on the Pharmacokinetics of Alogliptin</span></span></p>
<p>There are no clinically meaningful changes in the pharmacokinetics of alogliptin when NESINA is administered concomitantly with the drugs described below <span class="Italics">(Figure 2)</span>.</p>
<p><span class="Bold">Figure 2. Effect of Other Drugs on the Pharmacokinetic Exposure of Alogliptin</span></p>
<div class="Figure">
<a name="id14762768"></a><img alt="Figure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0&amp;name=d74fabc5-733f-4fbf-ad1c-d23fae6802fd-02.jpg">
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_9e10929a-81f8-4b33-90b6-dcc30cc27b1f"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_9539dfa9-cb3c-4057-9a5c-6e171e682d02"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Rats were administered oral doses of 75, 400 and 800 mg/kg alogliptin for two years. No drug-related tumors were observed up to 75 mg/kg or approximately 32 times the maximum recommended clinical dose of 25 mg, based on AUC exposure. At higher doses (approximately 308 times the maximum recommended clinical dose of 25 mg), a combination of thyroid C-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas increased in male but not female rats. No drug-related tumors were observed in mice after administration of 50, 150 or 300 mg/kg alogliptin for two years, or up to approximately 51 times the maximum recommended clinical dose of 25 mg, based on AUC exposure.</p>
<p>Alogliptin was not mutagenic or clastogenic, with and without metabolic activation, in the Ames test with <span class="Italics">S. typhimurium</span> and <span class="Italics">E. coli</span> or the cytogenetic assay in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells. Alogliptin was negative in the <span class="Italics">in vivo</span> mouse micronucleus study.</p>
<p>In a fertility study in rats, alogliptin had no adverse effects on early embryonic development, mating or fertility at doses up to 500 mg/kg, or approximately 172 times the clinical dose based on plasma drug exposure (AUC).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_01eab70c-9c39-45fd-a847-3c119cde8163"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">NESINA has been studied as monotherapy and in combination with metformin, a sulfonylurea, a thiazolidinedione (either alone or in combination with metformin or a sulfonylurea) and insulin (either alone or in combination with metformin).</p>
<p>A total of 8673 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were randomized in 10 double-blind, placebo- or active-controlled clinical safety and efficacy studies conducted to evaluate the effects of NESINA on glycemic control. The racial distribution of patients exposed to study medication was 68% Caucasian, 15% Asian, 7% Black and 9% other racial groups. The ethnic distribution was 30% Hispanic. Patients had an overall mean age of 55 years (range 21 to 80 years).</p>
<p>In patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, treatment with NESINA produced clinically meaningful and statistically significant improvements in A1C compared to placebo. As is typical for trials of agents to treat type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the mean reduction in A1C with NESINA appears to be related to the degree of A1C elevation at baseline.</p>
<p>NESINA had similar changes from baseline in serum lipids compared to placebo.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd3a9bac-fd24-4e7b-b6c1-4533750e0700"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Patients with Inadequate Glycemic Control on Diet and Exercise</h2>
<p class="First">A total of 1768 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in three double-blind studies to evaluate the efficacy and safety of NESINA in patients with inadequate glycemic control on diet and exercise. All three studies had a four-week, single-blind, placebo run-in period followed by a 26-week randomized treatment period. Patients who failed to meet prespecified hyperglycemic goals during the 26-week treatment periods received glycemic rescue therapy.</p>
<p>In a 26-week, double-blind, placebo-controlled study, a total of 329 patients (mean baseline A1C = 8%) were randomized to receive NESINA 12.5 mg, NESINA 25 mg or placebo once daily. Treatment with NESINA 25 mg resulted in statistically significant improvements from baseline in A1C and fasting plasma glucose (FPG) compared to placebo at Week 26 <span class="Italics">(Table 3)</span>. A total of 8% of patients receiving NESINA 25 mg and 30% of those receiving placebo required glycemic rescue therapy.</p>
<p>Improvements in A1C were not affected by gender, age or baseline BMI.</p>
<p>The mean change in body weight with NESINA was similar to placebo.</p>
<table width="100%">
<col width="46%">
<col width="27%">
<col width="27%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region and duration of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>p&lt;0.01 compared to placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 3. Glycemic Parameters at Week 26 in a Placebo-Controlled Monotherapy Study of NESINA</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">NESINA</span><br><span class="Bold">25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"> A1C (%) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=128</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=63</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline (adjusted mean<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Difference from placebo (adjusted mean<a href="#footnote-4" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a> (-0.8, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  % of patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">44% (58/131)<a href="#footnote-5" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">23% (15/64)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"> FPG (mg/dL) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=129</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=64</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">172</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">173</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline (adjusted mean<a href="#footnote-4" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-16</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">11</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Difference from placebo (adjusted mean<a href="#footnote-4" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-28<a href="#footnote-5" class="Sup">‡</a> (-40, -15)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
<p>In a 26-week, double-blind, active-controlled study, a total of 655 patients (mean baseline A1C = 8.8%) were randomized to receive NESINA 25 mg alone, pioglitazone 30 mg alone, NESINA 12.5 mg with pioglitazone 30 mg or NESINA 25 mg with pioglitazone 30 mg once daily. Coadministration of NESINA 25 mg with pioglitazone 30 mg resulted in statistically significant improvements from baseline in A1C and FPG compared to NESINA 25 mg alone and to pioglitazone 30 mg alone (<span class="Italics">Table 4</span>). A total of 3% of patients receiving NESINA 25 mg coadministered with pioglitazone 30 mg, 11% of those receiving NESINA 25 mg alone and 6% of those receiving pioglitazone 30 mg alone required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age or baseline BMI.</p>
<p>The mean increase in body weight was similar between pioglitazone alone and NESINA when coadministered with pioglitazone.</p>
<table width="100%">
<col width="45%">
<col width="18%">
<col width="18%">
<col width="18%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Intent-to-treat population using last observation carried forward</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Least squares means adjusted for treatment, geographic region and baseline value</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>p&lt;0.01 compared to NESINA 25 mg or pioglitazone 30 mg</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="4" valign="top"><p class="First"><span class="Bold">Table 4. Glycemic Parameters at Week 26 in an Active-Controlled Study of NESINA, Pioglitazone, and NESINA in Combination with Pioglitazone</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA</span><br><span class="Bold">25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">30 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+ Pioglitazone 30 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=160</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=153</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=158</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline <br>  adjusted mean<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Difference from <br>  NESINA 25 mg <br>  (adjusted mean<a href="#footnote-7" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.8<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a> (-1.0, -0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Difference from <br>  pioglitazone 30 mg <br>  (adjusted mean<a href="#footnote-7" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a href="#footnote-8" class="Sup">‡</a> (-0.8, -0.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  % of patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">24% (40/164)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">34% (55/163)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">63% (103/164)<a href="#footnote-8" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">FPG (mg/dL) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=162</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=157</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=162</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">189</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">189</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">185</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline <br>  (adjusted mean<a href="#footnote-7" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-26</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-37</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Difference from <br>  NESINA 25 mg <br>  (adjusted mean<a href="#footnote-7" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-24<a href="#footnote-8" class="Sup">‡</a> (-34, -15)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Difference from <br>  pioglitazone 30 mg <br>  (adjusted mean<a href="#footnote-7" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-13<a href="#footnote-8" class="Sup">‡</a> (-22, -4)</p></td>
</tr>
</tbody>
</table>
<p>In a 26-week, double-blind, placebo-controlled study, a total of 784 patients inadequately controlled on diet and exercise alone (mean baseline A1C = 8.4%) were randomized to one of seven treatment groups: placebo; metformin HCl 500 mg or metformin HCl 1000 mg twice daily; NESINA 12.5 mg twice daily; NESINA 25 mg daily; or NESINA 12.5 mg in combination with metformin HCl 500 mg or metformin HCl 1000 mg twice daily. Both coadministration treatment arms (NESINA 12.5 mg + metformin HCl 500 mg and NESINA 12.5 mg + metformin HCl 1000 mg) resulted in statistically significant improvements in A1C and FPG when compared with their respective individual alogliptin and metformin component regimens <span class="Italics">(Table 5)</span>. Coadministration treatment arms demonstrated improvements in two-hour postprandial glucose (PPG) compared to NESINA alone or metformin alone <span class="Italics">(Table 5)</span>. A total of 12.3% of patients receiving NESINA 12.5 mg + metformin HCl 500 mg, 2.6% of patients receiving NESINA 12.5 mg + metformin HCl 1000 mg, 17.3% of patients receiving NESINA 12.5 mg, 22.9% of patients receiving metformin HCl 500 mg, 10.8% of patients receiving metformin HCl 1000 mg and 38.7% of patients receiving placebo required glycemic rescue. </p>
<p>Improvements in A1C were not affected by gender, age, race or baseline BMI. The mean decrease in body weight was similar between metformin alone and NESINA when coadministered with metformin.</p>
<table width="100%">
<col width="29%">
<col width="9%">
<col width="10%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Intent-to-treat population using last observation on study prior to discontinuation of double-blind study medication or sulfonylurea rescue therapy for patients needing rescue</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Least squares means adjusted for treatment, geographic region and baseline value</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>p&lt;0.05 when compared to metformin and NESINA alone</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">§</a></dt>
<dd>Compared using logistic regression</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">¶</a></dt>
<dd>Intent-to-treat population using data available at Week 26</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top"><p class="First"><span class="Bold">Table 5. Glycemic Parameters at Week 26 for NESINA and Metformin Alone and in Combination in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First"><span class="Bold">NESINA</span></p>
<p><span class="Bold">12.5 mg</span><br><span class="Bold">Twice Daily</span></p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First"><span class="Bold">Metformin HCl</span></p>
<p><span class="Bold">500 mg</span><br><span class="Bold">Twice Daily</span></p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First"><span class="Bold">Metformin HCl</span></p>
<p><span class="Bold">1000 mg</span><br><span class="Bold">Twice Daily</span></p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First"><span class="Bold">NESINA</span></p>
<p><span class="Bold">12.5 mg</span></p>
<p><span class="Bold">+ Metformin HCl</span></p>
<p><span class="Bold">500 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">NESINA</span></p>
<p><span class="Bold">12.5 mg</span></p>
<p><span class="Bold">+ Metformin HCl</span></p>
<p><span class="Bold">1000 mg</span></p>
<p><span class="Bold">Twice Daily</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=102</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=104</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=103</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=108</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=102</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=111</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">8.4</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">8.4</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top">
<p class="First">Change from baseline </p>
<p>(adjusted mean<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">0.1</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-0.6</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-0.7</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-1.1</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-1.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from metformin (adjusted mean<a href="#footnote-10" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">-0.6<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a></p>
<p>(-0.9, -0.3)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-0.4<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-0.7, -0.2)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from NESINA (adjusted mean<a href="#footnote-10" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">-0.7<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-1.0, -0.4)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-1.0<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-1.3, -0.7)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top">
<p class="First">% of patients (n/N) achieving</p>
<p>A1C &lt;7%<a name="footnote-reference-12" href="#footnote-12" class="Sup">§</a></p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">4%</p>
<p>(4/102)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">20%</p>
<p>(21/104)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">27%</p>
<p>(28/103)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">34%</p>
<p>(37/108)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">47%<a href="#footnote-11" class="Sup">‡</a></p>
<p>(48/102)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">59%<a href="#footnote-11" class="Sup">‡</a></p>
<p>(66/111)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span><a href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=105</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=106</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=106</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=110</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=106</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=112</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">187</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">177</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">180</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">181</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">176</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">185</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top">
<p class="First">Change from baseline </p>
<p>(adjusted mean<a href="#footnote-10" class="Sup">†</a>)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-10</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-12</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-32</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-46</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from metformin (adjusted mean<a href="#footnote-10" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">-20<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-33, -8)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-14<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-26, -2)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from NESINA (adjusted mean<a href="#footnote-10" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">-22<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-35, -10)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-36<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-49, -24)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">2-Hour PPG (mg/dL)</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">¶</a></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=26</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=34</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=28</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=37</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">N=31</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=37</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">263</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">272</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">247</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">266</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">261</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">268</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top">
<p class="First">Change from baseline </p>
<p>(adjusted mean<a href="#footnote-10" class="Sup">†</a>)</p>
</td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-21</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-43</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-49</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-54</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-68</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-86<a href="#footnote-11" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from metformin (adjusted mean<a href="#footnote-10" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">-19</p>
<p>(-49, 11)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-32<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-58, -5)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Difference from NESINA (adjusted mean<a href="#footnote-10" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center" valign="middle">
<p class="First">-25</p>
<p>(-53, -3)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First">-43<a href="#footnote-11" class="Sup">‡</a></p>
<p>(-70, -16)</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b24da8b-730f-4088-b12d-0f9fe56e3852"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Combination Therapy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61f48b1e-eab6-404d-9e1f-26cf817e38ad"></a><a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Add-On Therapy to Metformin</span></span></p>
<p>A total of 2081 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> participated in two 26-week, double-blind, placebo-controlled studies to evaluate the efficacy and safety of NESINA as add-on therapy to metformin. In both studies, patients were inadequately controlled on metformin at a dose of at least 1500 mg per day or at the maximum tolerated dose. All patients entered a four-week, single-blind placebo run-in period prior to randomization. Patients who failed to meet prespecified hyperglycemic goals during the 26-week treatment periods received glycemic rescue therapy.</p>
<p>In the first 26-week, placebo-controlled study, a total of 527 patients already on metformin (mean baseline A1C = 8%) were randomized to receive NESINA 12.5 mg, NESINA 25 mg or placebo. Patients were maintained on a stable dose of metformin (median dose = 1700 mg) during the treatment period. NESINA 25 mg in combination with metformin resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, when compared to placebo <span class="Italics">(Table 6)</span>. A total of 8% of patients receiving NESINA 25 mg and 24% of patients receiving placebo required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age, baseline BMI or baseline metformin dose.</p>
<p>The mean decrease in body weight was similar between NESINA and placebo when given in combination with metformin.</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region and baseline metformin dose</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">‡</a></dt>
<dd>p&lt;0.001 compared to placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 6. Glycemic Parameters at Week 26 in a Placebo-Controlled Study of NESINA as Add-On Therapy to Metformin</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+ Metformin</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=203</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=103</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline <br>  (adjusted mean<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-15" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a name="footnote-reference-16" href="#footnote-16" class="Sup">‡</a> (-0.7, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  % of patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">44% (92/207)<a href="#footnote-16" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">18% (19/104)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=204</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=104</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">172</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">180</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Change from baseline <br>  (adjusted mean<a href="#footnote-15" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-17</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-15" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-17<a href="#footnote-16" class="Sup">‡</a> (-26, -9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
<p>In the second 26-week, double-blind, placebo-controlled study, a total of 1554 patients already on metformin (mean baseline A1C = 8.5%) were randomized to one of 12 double-blind treatment groups: placebo; 12.5 mg or 25 mg of NESINA alone; 15 mg, 30 mg or 45 mg of pioglitazone alone; or 12.5 mg or 25 mg of NESINA in combination with 15 mg, 30 mg or 45 mg of pioglitazone. Patients were maintained on a stable dose of metformin (median dose = 1700 mg) during the treatment period. Coadministration of NESINA and pioglitazone provided statistically significant improvements in A1C and FPG compared to placebo, to NESINA alone or to pioglitazone alone when added to background metformin therapy (<span class="Italics">Table 7, Figure 3</span>). In addition, improvements from baseline A1C were comparable between NESINA alone and pioglitazone alone (15 mg, 30 mg and 45 mg) at Week 26. A total of 4%, 5% or 2% of patients receiving NESINA 25 mg with 15 mg, 30 mg or 45 mg pioglitazone, 33% of patients receiving placebo, 13% of patients receiving NESINA 25 mg and 10%, 15% or 9% of patients receiving pioglitazone 15 mg, 30 mg or 45 mg alone required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age or baseline BMI.</p>
<p>The mean increase in body weight was similar between pioglitazone alone and NESINA when coadministered with pioglitazone.</p>
<table width="100%">
<col width="11%">
<col width="8%">
<col width="9%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">†</a></dt>
<dd>Least squares means adjusted for treatment, geographic region, metformin dose and baseline value</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">‡</a></dt>
<dd>p≤0.01 when compared to corresponding doses of pioglitazone and NESINA alone</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="9" valign="top"><p class="First"><span class="Bold">Table 7. Glycemic Parameters in a 26-Week Study of NESINA, Pioglitazone and NESINA in Combination with Pioglitazone when Added to Metformin</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA</span><br><span class="Bold">25 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">15 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">30 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone</span><br><span class="Bold">45 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA</span><br><span class="Bold">25 mg</span><br><span class="Bold">+</span><span class="Bold">Pioglitazone</span><br><span class="Bold">15 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA</span><br><span class="Bold">25 mg</span><br><span class="Bold">+ Pioglitazone</span><br><span class="Bold">30 mg</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA</span><br><span class="Bold">25 mg</span><br><span class="Bold">+</span><span class="Bold">Pioglitazone</span><br><span class="Bold">45 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=123</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=123</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=124</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Baseline <br>(mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from baseline <br>(adjusted mean<a name="footnote-reference-18" href="#footnote-18" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.3<a name="footnote-reference-19" href="#footnote-19" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.4<a href="#footnote-19" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-1.6<a href="#footnote-19" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from pioglitazone <br>(adjusted mean<a href="#footnote-18" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" valign="middle"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a href="#footnote-19" class="Sup">‡</a> (-0.7, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a href="#footnote-19" class="Sup">‡</a> (-0.7, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a href="#footnote-19" class="Sup">‡</a> (-0.8,<br>-0.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from NESINA (adjusted mean<a href="#footnote-18" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.4<a href="#footnote-19" class="Sup">‡</a> (-0.6, -0.1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a href="#footnote-19" class="Sup">‡</a> (-0.7, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.7<a href="#footnote-19" class="Sup">‡</a> (-0.9,<br>-0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Patients (%) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6%<br>(8/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">27%<br>(35/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">26%<br>(33/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">30%<br>(38/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">36%<br>(47/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">55%<br>(71/130)<a href="#footnote-19" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">53%<br>(69/130)<a href="#footnote-19" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">60%<br>(78/130)<a href="#footnote-19" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=129</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=125</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=129</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=130</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Baseline <br>(mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">177</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">184</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">177</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">175</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">181</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">179</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">179</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">178</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Change from baseline <br>(adjusted mean<a href="#footnote-18" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-19</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-24</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-29</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-38<a href="#footnote-19" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-42<a href="#footnote-19" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-53<a href="#footnote-19" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from pioglitazone <br>(adjusted mean<a href="#footnote-18" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-14<a href="#footnote-19" class="Sup">‡</a> (-24, -5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-13<a href="#footnote-19" class="Sup">‡</a> (-23, -3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-20<a href="#footnote-19" class="Sup">‡</a> (-30,<br>-11)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Difference from NESINA (adjusted mean<a href="#footnote-18" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-19<a href="#footnote-19" class="Sup">‡</a> (-29, -10)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-23<a href="#footnote-19" class="Sup">‡</a> (-33, -13)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-34<a href="#footnote-19" class="Sup">‡</a> (-44,<br>-24)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 3. Change from Baseline in A1C at Week 26 with NESINA and Pioglitazone Alone and NESINA in Combination with Pioglitazone When Added to Metformin</span></p>
<div class="Figure">
<a name="id14773753"></a><img alt="Figure3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0&amp;name=d74fabc5-733f-4fbf-ad1c-d23fae6802fd-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8148ce6d-6e5a-4b69-a296-3e1df5ebd285"></a><a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Add-On Therapy to a Thiazolidinedione</span></span></p>
<p>In a 26-week, placebo-controlled study, a total of 493 patients inadequately controlled on a thiazolidinedione alone or in combination with metformin or a sulfonylurea (10 mg) (mean baseline A1C = 8%) were randomized to receive NESINA 12.5 mg, NESINA 25 mg or placebo. Patients were maintained on a stable dose of pioglitazone (median dose = 30 mg) during the treatment period; those who were also previously treated on metformin (median dose = 2000 mg) or sulfonylurea (median dose = 10 mg) prior to randomization were maintained on the combination therapy during the treatment period. All patients entered into a four-week, single-blind placebo run-in period prior to randomization. Patients who failed to meet prespecified hyperglycemic goals during the 26-week treatment period received glycemic rescue therapy.</p>
<p>The addition of NESINA 25 mg once daily to pioglitazone therapy resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, compared to placebo (<span class="Italics">Table 8</span>). A total of 9% of patients who were receiving NESINA 25 mg and 12% of patients receiving placebo required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age, baseline BMI or baseline pioglitazone dose.</p>
<p>Clinically meaningful reductions in A1C were observed with NESINA compared to placebo regardless of whether subjects were receiving concomitant metformin or sulfonylurea (-0.2% placebo versus -0.9% NESINA) therapy or pioglitazone alone (0% placebo versus -0.52% NESINA).</p>
<p>The mean increase in body weight was similar between NESINA and placebo when given in combination with pioglitazone.</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region, baseline treatment regimen (pioglitazone, pioglitazone + metformin or pioglitazone + sulfonylurea) and baseline pioglitazone dose</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">‡</a></dt>
<dd>p&lt;0.01 compared to placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 8. Glycemic Parameters in a 26-Week, Placebo-Controlled Study of NESINA as Add-On Therapy to Pioglitazone</span><a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+</span><span class="Bold">Pioglitazone</span><br><span class="Bold">± Metformin ± Sulfonylurea</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+</span><span class="Bold">Pioglitazone</span><br><span class="Bold">± Metformin ± Sulfonylurea</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=195</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=95</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline <br>  (adjusted mean<a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-21" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a name="footnote-reference-22" href="#footnote-22" class="Sup">‡</a> (-0.8, -0.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  % of patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">49% (98/199)<a href="#footnote-22" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">34% (33/97)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=197</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=97</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">170</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">172</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Change from baseline <br>  (adjusted mean<a href="#footnote-21" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-20</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-21" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-14<a href="#footnote-22" class="Sup">‡</a> (-23, -5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b07a4f0-cf47-4979-8f4d-b5c656a3e03b"></a><a name="section-13.2.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Add-on Combination Therapy with Pioglitazone and Metformin </span></span></p>
<p>In a 52-week, active-comparator study, a total of 803 patients inadequately controlled (mean baseline A1C = 8.2%) on a current regimen of pioglitazone 30 mg and metformin at least 1500 mg per day or at the maximum tolerated dose were randomized to either receive the addition of NESINA 25 mg or the titration of pioglitazone 30 mg to 45 mg following a four-week, single-blind placebo run-in period. Patients were maintained on a stable dose of metformin (median dose = 1700 mg). Patients who failed to meet prespecified hyperglycemic goals during the 52-week treatment period received glycemic rescue therapy.</p>
<p>In combination with pioglitazone and metformin, NESINA 25 mg was shown to be statistically superior in lowering A1C and FPG compared with the titration of pioglitazone from 30 mg to 45 mg at Week 26 and at Week 52 (<span class="Italics">Table 9; results shown only for Week 52</span>). A total of 11% of patients in the NESINA 25 mg treatment group and 22% of patients in the pioglitazone up-titration group required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age, race or baseline BMI.</p>
<p>The mean increase in body weight was similar in both treatment arms.</p>
<table width="100%">
<col width="50%">
<col width="26%">
<col width="24%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region and baseline metformin dose.</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">‡</a></dt>
<dd>Noninferior and statistically superior to metformin + pioglitazone at the 0.025 one-sided significance level</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">§</a></dt>
<dd>p&lt;0.001 compared to pioglitazone 45 mg + metformin</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 9. Glycemic Parameters in a 52-Week, Controlled Study of NESINA as Add-On Combination Therapy with Pioglitazone and Metformin</span><a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+</span><span class="Bold">Pioglitazone 30 mg</span><br><span class="Bold">+</span><span class="Bold">Metformin</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Pioglitazone 45 mg</span><br><span class="Bold">+</span><span class="Bold">Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=397</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=394</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline (adjusted mean<a name="footnote-reference-24" href="#footnote-24" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First">  Difference from pioglitazone 45 mg + metformin (adjusted mean<a href="#footnote-24" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">-0.4<a name="footnote-reference-25" href="#footnote-25" class="Sup">‡</a> (-0.5, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  % of patients (n/N) achieving A1C≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">33% (134/404)<a name="footnote-reference-26" href="#footnote-26" class="Sup">§</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">21% (85/399)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL) </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=399</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=396</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">162</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">162</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Change from baseline (adjusted mean<a href="#footnote-24" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-15</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First">  Difference from pioglitazone 45 mg + metformin (adjusted mean<a href="#footnote-24" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">-11<a href="#footnote-26" class="Sup">§</a> (-16, -6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d6238aa-9d0a-46bd-a672-17f7edbb5661"></a><a name="section-13.2.4"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Add-On Therapy to a Sulfonylurea</span></span></p>
<p>In a 26-week, placebo-controlled study, a total of 500 patients inadequately controlled on a sulfonylurea (mean baseline A1C = 8.1%) were randomized to receive NESINA 12.5 mg, NESINA 25 mg or placebo. Patients were maintained on a stable dose of glyburide (median dose = 10 mg) during the treatment period. All patients entered into a four-week, single-blind, placebo run-in period prior to randomization. Patients who failed to meet prespecified hyperglycemic goals during the 26-week treatment period received glycemic rescue therapy.</p>
<p>The addition of NESINA 25 mg to glyburide therapy resulted in statistically significant improvements from baseline in A1C at Week 26 when compared to placebo <span class="Italics">(Table 10)</span>. Improvements in FPG observed with NESINA 25 mg were not statistically significant compared with placebo. A total of 16% of patients receiving NESINA 25 mg and 28% of those receiving placebo required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age, baseline BMI or baseline glyburide dose.</p>
<p>The mean change in body weight was similar between NESINA and placebo when given in combination with glyburide.</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-27" href="#footnote-reference-27">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region and baseline glyburide dose</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">‡</a></dt>
<dd>p&lt;0.01 compared to placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 10. Glycemic Parameters in a 26-Week, Placebo-Controlled Study of NESINA as Add-On Therapy to Glyburide</span><a name="footnote-reference-27" href="#footnote-27" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+</span><span class="Bold">Glyburide</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+</span><span class="Bold">Glyburide</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=197</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=97</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline <br>  (adjusted mean<a name="footnote-reference-28" href="#footnote-28" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-28" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.5<a name="footnote-reference-29" href="#footnote-29" class="Sup">‡</a> (-0.7, -0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  % of patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">35% (69/198)<a href="#footnote-29" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">18% (18/99)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=198</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=99</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">174</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">177</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Change from baseline <br>  (adjusted mean<a href="#footnote-28" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-28" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-11 (-22, 1)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7420dee3-7f40-4361-8f1e-c7d88a431f1f"></a><a name="section-13.2.5"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Add-On Therapy to Insulin</span></span></p>
<p>In a 26-week, placebo-controlled study, a total of 390 patients inadequately controlled on insulin alone (42%) or in combination with metformin (58%) (mean baseline A1C = 9.3%) were randomized to receive NESINA 12.5 mg, NESINA 25 mg or placebo. Patients were maintained on their insulin regimen (median dose = 55 IU) upon randomization and those previously treated with insulin in combination with metformin (median dose = 1700 mg) prior to randomization continued on the combination regimen during the treatment period. Patients entered the trial on short-, intermediate- or long-acting (basal) insulin or premixed insulin. Patients who failed to meet prespecified hyperglycemic goals during the 26-week treatment period received glycemic rescue therapy.</p>
<p>The addition of NESINA 25 mg once daily to insulin therapy resulted in statistically significant improvements from baseline in A1C and FPG at Week 26, when compared to placebo <span class="Italics">(Table 11)</span>. A total of 20% of patients receiving NESINA 25 mg and 40% of those receiving placebo required glycemic rescue.</p>
<p>Improvements in A1C were not affected by gender, age, baseline BMI or baseline insulin dose. Clinically meaningful reductions in A1C were observed with NESINA compared to placebo regardless of whether subjects were receiving concomitant metformin and insulin (-0.2% placebo versus -0.8% NESINA) therapy or insulin alone (0.1% placebo versus -0.7% NESINA).</p>
<p>The mean increase in body weight was similar between NESINA and placebo when given in combination with insulin.</p>
<table width="100%">
<col width="45%">
<col width="28%">
<col width="27%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-30" href="#footnote-reference-30">*</a></dt>
<dd>Intent-to-treat population using last observation on study</dd>
<dt><a name="footnote-31" href="#footnote-reference-31">†</a></dt>
<dd>Least squares means adjusted for treatment, baseline value, geographic region, baseline treatment regimen (insulin or insulin + metformin)  and baseline daily insulin dose</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">‡</a></dt>
<dd>p&lt;0.05 compared to placebo</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 11. Glycemic Parameters in a 26-Week, Placebo-Controlled Study of NESINA as Add-On Therapy to Insulin</span><a name="footnote-reference-30" href="#footnote-30" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">NESINA 25 mg</span><br><span class="Bold">+</span><span class="Bold">Insulin ± Metformin</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+</span><span class="Bold">Insulin ± Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">A1C (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=126</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">9.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">  Change from baseline <br>  (adjusted mean<a name="footnote-reference-31" href="#footnote-31" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-31" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-0.6<a name="footnote-reference-32" href="#footnote-32" class="Sup">‡</a> (-0.8, -0.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  % of patients (n/N) achieving A1C ≤7%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8% (10/129)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">1% (1/129)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=128</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">N=127</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Baseline (mean)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">186</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">196</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Change from baseline <br>  (adjusted mean<a href="#footnote-31" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-12</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">  Difference from placebo <br>  (adjusted mean<a href="#footnote-31" class="Sup">†</a> with 95% confidence interval)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-18<a href="#footnote-32" class="Sup">‡</a> (-33, -2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_af79bd80-c219-47b7-bdca-66cb701f0ee4"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NESINA tablets are available as film-coated tablets containing 25 mg, 12.5 mg or 6.25 mg of alogliptin as follows:</p>
<p>25 mg tablet: light red, oval, biconvex, film-coated, with "TAK ALG-25" printed on one side, available in:</p>
<table width="100%">
<col width="49%">
<col width="51%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-250-30</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-250-90</p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-250-50</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>12.5 mg tablet: yellow, oval, biconvex, film-coated, with "TAK ALG-12.5" printed on one side, available in:</p>
<table width="100%">
<col width="49%">
<col width="51%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-125-30</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr>
<td valign="top"><p class="First">NDC 64764-125-90</p></td>
<td valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-125-50</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 500 tablets</p></td>
</tr>
</tbody>
</table>
<p>6.25 mg tablet: light pink, oval, biconvex, film-coated, with "TAK ALG-6.25" printed on one side, available in:</p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">NDC 64764-625-30</p></td>
<td class="Toprule" valign="top"><p class="First">Bottles of 30 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">NDC 64764-625-90</p></td>
<td class="Botrule" valign="top"><p class="First">Bottles of 90 tablets</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_36954ba2-e0dc-4843-b519-f72a731ff62f"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_6db188da-9ca0-4010-ada8-af876978d6a7"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling (Medication Guide)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5993393-7099-4f5a-84b9-99e7e8a6371c"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Instructions</h2>
<p class="First">Inform patients of the potential risks and benefits of NESINA.</p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span> has been reported during use of NESINA. Patients should be informed that persistent, severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, sometimes radiating to the back, which may or may not be accompanied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, is the hallmark symptom of <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. Patients should be instructed to promptly discontinue NESINA and contact their physician if persistent severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> occurs.</p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported during use of NESINA. If symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue and throat that may cause difficulty in breathing or swallowing) occur, patients should be instructed to discontinue NESINA and seek medical advice promptly.</p>
<p>Patients should be informed that postmarketing reports of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, sometimes fatal, have been reported during use of NESINA. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> occur, patients should be instructed to discontinue NESINA and seek medical advice promptly. </p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> can occur, particularly when an insulin secretagogue or insulin is used in combination with NESINA. Explain the risks, symptoms and appropriate management of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>Inform patients that severe and disabling <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> may occur with this class of drugs. The time to onset of symptoms can range from one day to years. Instruct patients to seek medical advice if severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> occurs.</p>
<p>Instruct patients to take NESINA only as prescribed. If a dose is missed, advise patients not to double their next dose.</p>
<p>Instruct patients to read the Medication Guide before starting NESINA therapy and to reread each time the prescription is refilled. Instruct patients to inform their healthcare provider if an unusual symptom develops or if a symptom persists or worsens.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27a648da-c5c8-4894-a0fb-2d84f475e189"></a><a name="section-16"></a><p></p>
<p class="First">Revised: August 2015</p>
<p>NES011 R4</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_f55bfa58-3ea6-43a2-9bfd-6730aa971933"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">NESINA (nes-see′-na)</span><br><span class="Bold">(alogliptin)</span></p>
<p><span class="Bold">tablets</span></p>
<p>Read this Medication Guide carefully before you start taking NESINA and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment. If you have any questions about NESINA, ask your doctor or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about NESINA?</span></p>
<p><span class="Bold">Serious side effects can happen to people taking NESINA,</span> including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>), which may be severe. </p>
<p>Certain medical conditions make you more likely to get <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<p><span class="Bold">Before you start taking NESINA:</span></p>
<p>Tell your doctor if you have ever had:</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>stones in your gallbladder (<span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>a history of <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span></dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>•</dt>
<dd>kidney problems</dd>
</dl></td>
<td valign="top"><dl>
<dt>•</dt>
<dd>liver problems</dd>
</dl></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
<p>Stop taking NESINA and call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach area (abdomen) that is severe and will not go away. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may be felt going from your abdomen through to your back. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may happen with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These may be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
<dl>
<dt> </dt>
<dd><span class="Bold">What is NESINA?</span></dd>
</dl>
<dl>
<dt>•</dt>
<dd>NESINA is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </dd>
<dt>•</dt>
<dd>NESINA is unlikely by itself to cause your blood sugar to be lowered to a dangerous level (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). However, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may still occur with NESINA. </dd>
<dt>•</dt>
<dd>NESINA is not for people with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</dd>
<dt>•</dt>
<dd>NESINA is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in blood or urine).</dd>
</dl>
<p>It is not known if NESINA is safe and effective in children under the age of 18.</p>
<p><span class="Bold">Who should not take NESINA?</span></p>
<p><span class="Bold">Do not take NESINA if you:</span></p>
<dl>
<dt>•</dt>
<dd>Are allergic to any ingredients in NESINA or have had a serious allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reaction to NESINA. See the end of this Medication Guide for a complete list of the ingredients in NESINA.</dd>
<dt>•</dt>
<dd>Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to NESINA may include:</dd>
</dl>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat and other areas on your skin</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>difficulty with swallowing or breathing</dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<p>If you have any of these symptoms, stop taking NESINA and contact your doctor or go to the nearest hospital emergency room right away.</p>
<p><span class="Bold">What should I tell my doctor before and during treatment with NESINA?</span></p>
<p>Before you take NESINA, tell your doctor if you:</p>
<dl>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of your pancreas (<span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>) </dd>
<dt>•</dt>
<dd>have kidney or liver problems </dd>
<dt>•</dt>
<dd>have other medical conditions</dd>
<dt>•</dt>
<dd>
<span class="Bold">are pregnant or plan to become pregnant</span>. It is not known if NESINA can harm your unborn baby. Talk with your doctor about the best way to control your blood sugar while you are pregnant or if you plan to become pregnant</dd>
<dt>•</dt>
<dd>
<span class="Bold">are breastfeeding or plan to breastfeed</span>. It is not known whether NESINA passes into your breast milk. Talk with your doctor about the best way to feed your baby if you are taking NESINA</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins and herbal supplements.</p>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist before you start any new medicine.</p>
<p>NESINA may affect the way other medicines work, and other medicines may affect how NESINA works. Contact your doctor before you start or stop other types of medicines.</p>
<p><span class="Bold">How should I take NESINA?</span></p>
<dl>
<dt>•</dt>
<dd>Take NESINA exactly as your doctor tells you to take it.</dd>
<dt>•</dt>
<dd>Take NESINA 1 time each day with or without food.</dd>
<dt>•</dt>
<dd>If you miss a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose, and take the next dose at your regular time. <span class="Bold">Do not</span> take 2 doses of NESINA at the same time</dd>
<dt>•</dt>
<dd>If you take too much NESINA, call your doctor or go to the nearest hospital emergency room right away</dd>
<dt>•</dt>
<dd>If your body is under stress, such as from <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span> or surgery, the dose of your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicines may need to be changed. Call your doctor right away </dd>
<dt>•</dt>
<dd>Stay on your diet and exercise programs and check your blood sugar as your doctor tells you to</dd>
<dt>•</dt>
<dd>Your doctor may do certain blood tests before you start NESINA and during treatment as needed. Your doctor may change your dose of NESINA based on the results of your blood tests due to how well your kidneys are working</dd>
<dt>•</dt>
<dd>Your doctor will check your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with regular blood tests, including your blood sugar levels and your hemoglobin A1C</dd>
</dl>
<p><span class="Bold">What are the possible side effects of NESINA?</span></p>
<p><span class="Bold">NESINA can cause serious side effects, including:</span></p>
<p>See “<span class="Bold">What is the most important information I should know about NESINA?</span>?</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>) reactions </span>such as:</dd>
</dl>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, throat and other areas on your skin</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>difficulty swallowing or breathing</dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>raised, red areas on your skin (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>)</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, flaking or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span></dd>
</dl></td>
</tr>
</tbody>
</table>
<p>     If you have these symptoms, stop taking NESINA and contact your doctor right away.</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Liver problems. </span>Call your doctor right away if you have unexplained symptoms, such as:</dd>
</dl>
<table width="100%">
<col width="33%">
<col width="26%">
<col width="40%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>unusual or unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
</dl></td>
</tr>
<tr class="Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>loss of appetite</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>dark urine</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>yellowing of your skin or the whites of your eyes</dd>
</dl></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)</span>. If you take NESINA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take NESINA. If you have symptoms of low blood sugar, you should check your blood sugar and treat if low, then call your doctor. Signs and symptoms of low blood sugar include:</dd>
</dl>
<table width="100%">
<col width="20%">
<col width="20%">
<col width="21%">
<col width="20%">
<col width="19%">
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Shaking</span> or <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">feeling jittery</span> </dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>change in mood</dd>
</dl></td>
</tr>
<tr class="Botrule Last">
<td valign="top"><dl>
<dt>o</dt>
<dd>fast heartbeat</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd>change in vision</dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
</dl></td>
<td valign="top"><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
</dl></td>
<td valign="top"></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint pain</span>. </span>Some people who take medicines called DPP-4 inhibitors like NESINA may develop <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span> that can be severe.  Call your doctor if you have severe <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>.<span class="Bold"></span>
</dd>
</dl>
<p>The most common side effects of NESINA include stuffy or <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms (<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>).</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of NESINA. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store NESINA?</span></p>
<p>Store NESINA at room temperature between 68°F to 77°F (20°C to 25°C).</p>
<p><span class="Bold">Keep NESINA and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of NESINA</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not take NESINA for a condition for which it was not prescribed. Do not give NESINA to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about NESINA. If you would like to know more information, talk with your doctor. You can ask your doctor or pharmacist for information about NESINA that is written for health professionals.</p>
<p>For more information go to www.NESINA.com or call 1-877-TAKEDA-7 (1-877-825-3327).</p>
<p><span class="Bold">What are the ingredients in NESINA?</span></p>
<p><span class="Bold">Active ingredient:</span> alogliptin</p>
<p><span class="Bold">Inactive ingredients:</span> mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium and magnesium stearate. In addition, the film-coating contains the following inactive ingredients: hypromellose, titanium dioxide, ferric oxide (red or yellow) and polyethylene glycol and is marked with gray F1 printing ink</p>
<p>Distributed by:<br><span class="Bold">Takeda Pharmaceuticals America, Inc</span>.<br>Deerfield, IL 60015</p>
<p>NESINA is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and is used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>© 2013 - 2015 Takeda Pharmaceuticals America, Inc.</p>
<p>NES011 R4</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.                      8/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b17e92bc-b655-4c24-86e5-8a1eed22d0ff"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 6.25 MG</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">625</span>-30</p>
<p><span class="Bold">Nesina</span></p>
<p><span class="Bold">(alogliptin) tablets</span></p>
<p><span class="Bold">6.25 mg</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">30 Tablets</span></p>
<p>Takeda logo</p>
<p><span class="Bold">Rx Only</span></p>
<div class="Figure">
<a name="id27748862"></a><img alt="6-25bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0&amp;name=d74fabc5-733f-4fbf-ad1c-d23fae6802fd-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d3480999-ac28-4771-8dff-6a5ccaf0e893"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 12.5 MG</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">125</span>-30</p>
<p><span class="Bold">Nesina</span></p>
<p><span class="Bold">(alogliptin) tablets</span></p>
<p><span class="Bold">12.5 mg</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">30 Tablets</span></p>
<p>Takeda logo</p>
<p><span class="Bold">Rx Only</span></p>
<div class="Figure">
<a name="id27747565"></a><img alt="12-5bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0&amp;name=d74fabc5-733f-4fbf-ad1c-d23fae6802fd-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4aa562f2-1923-4921-86d0-531144c43c28"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 MG</span></p>
<p><span class="Bold">NDC</span> 64764-<span class="Bold">250</span>-30</p>
<p><span class="Bold">Nesina</span></p>
<p><span class="Bold">(alogliptin) tablets</span></p>
<p><span class="Bold">25 mg</span></p>
<p><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">30 Tablets</span></p>
<p>Takeda logo</p>
<p><span class="Bold">Rx Only</span></p>
<div class="Figure">
<a name="id27746268"></a><img alt="25bottlelabel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3768c7e-aa4c-44d3-bc53-43bb7346c0b0&amp;name=d74fabc5-733f-4fbf-ad1c-d23fae6802fd-07.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NESINA 		
					</strong><br><span class="contentTableReg">alogliptin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-625</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">6.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (light pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TAK;ALG;6;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-625-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-625-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022271</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NESINA 		
					</strong><br><span class="contentTableReg">alogliptin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-125</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TAK;ALG;12;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-125-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-125-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-125-50</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-125-02</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022271</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NESINA 		
					</strong><br><span class="contentTableReg">alogliptin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-250</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ALOGLIPTIN BENZOATE</strong> (ALOGLIPTIN) </td>
<td class="formItem">ALOGLIPTIN</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE L)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (light red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TAK;ALG;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-250-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-250-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-250-50</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-250-02</td>
<td class="formItem">4  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022271</td>
<td class="formItem">01/25/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Takeda Pharmaceuticals America, Inc.
							(830134016)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2b75dae8-cf8b-4b90-83c2-0a9ea7451306</div>
<div>Set id: a3768c7e-aa4c-44d3-bc53-43bb7346c0b0</div>
<div>Version: 6</div>
<div>Effective Time: 20150831</div>
</div>
</div> <div class="DistributorName">Takeda Pharmaceuticals America, Inc.</div></p>
</body></html>
